Terrie Curran

Terrie Curran, listed as chief executive, has filed trades across 4 companies (mainly through SEC (Form 4)), most often in Celgene Corp /DE/, Phathom Pharmaceuticals, Inc. and Arcutis Biotherapeutics, Inc. We count 58 filings; the first trade dates from 1 August 2017 and the latest from 27 August 2026.

The open-market side counts 2 purchases for €239k alongside 18 sales for €4.4M. Sales outweigh purchases by €4.2M. Buying on the open market means paying the going price with one's own funds, a different act from receiving shares as pay. Outside the open market, there are 21 share grants and 14 option exercises. In 2026 alone, the filings show no purchases and 3 sales.

The record was last updated on 28 August 2026 with an option exercise (€200k) in Arcutis Biotherapeutics, Inc. The latest purchase dates back some time: it was published 1,296 days ago, on 7 April 2023. Between a trade and the moment it shows up on SEC (Form 4), the median delay is 2 days. Section 16 rules allow two business days to file each Form 4. Selling is not necessarily a view on the stock: liquidity needs and diversification are common motives. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.